Similar articles for PMID: 10636148

Year	Number of Results
1993	2
1994	2
1995	2
1996	5
1997	3
1998	4
1999	10
2000	13
2001	9
2002	5
2003	7
2004	7
2005	14
2006	5
2007	5
2008	7
2009	8
2010	4
2011	3
2012	7
2013	3
2014	5
2016	1
2017	1
2018	2
2019	1
2020	2
2022	2
2023	1
2024	0

1

Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group.

Zhao GJ, Koopmans RA, Li DK, Bedell L, Paty DW. Zhao GJ, et al. Neurology. 2000 Jan 11;54(1):200-6. doi: 10.1212/wnl.54.1.200. Neurology. 2000. PMID: 10636148 Clinical Trial.

2

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T. Hurwitz BJ, et al. Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013. Clin Ther. 2008. PMID: 18640466 Clinical Trial.

3

Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.

McCormack PL, Scott LJ. McCormack PL, et al. BioDrugs. 2004;18(5):343-7. doi: 10.2165/00063030-200418050-00006. BioDrugs. 2004. PMID: 15377176 Review.

4

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.

Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, Clerico M, Pipieri A, Verdun E, Giordano L, Durelli L; INCOMIN Trial Study Group. Barbero P, et al. Mult Scler. 2006 Feb;12(1):72-6. doi: 10.1191/135248506ms1247oa. Mult Scler. 2006. PMID: 16459722 Clinical Trial.

5

The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.

Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; OPTIMS Study Group. Durelli L, et al. J Neurol. 2008 Sep;255(9):1315-23. doi: 10.1007/s00415-008-0879-6. Epub 2008 Sep 25. J Neurol. 2008. PMID: 18825438 Clinical Trial.

6

Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.

McCormack PL, Scott LJ. McCormack PL, et al. CNS Drugs. 2004;18(8):521-46. doi: 10.2165/00023210-200418080-00004. CNS Drugs. 2004. PMID: 15182221 Review.

7

A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.

Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators. Clanet M, et al. Neurology. 2002 Nov 26;59(10):1507-17. doi: 10.1212/01.wnl.0000032256.35561.d6. Neurology. 2002. PMID: 12451189 Clinical Trial.

8

A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.

Jeffery DR, Chepuri N, Durden D, Burdette J. Jeffery DR, et al. Mult Scler. 2005 Jun;11(3):296-301. doi: 10.1191/1352458505ms1154oa. Mult Scler. 2005. PMID: 15957510 Clinical Trial.

9

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

Panitch H, Miller A, Paty D, Weinshenker B; North American Study Group on Interferon beta-1b in Secondary Progressive MS. Panitch H, et al. Neurology. 2004 Nov 23;63(10):1788-95. doi: 10.1212/01.wnl.0000146958.77317.3e. Neurology. 2004. PMID: 15557491 Clinical Trial.

10

Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis.

Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K. Miller DH, et al. Ann Neurol. 1999 Dec;46(6):850-9. doi: 10.1002/1531-8249(199912)46:6<850::aid-ana7>3.0.co;2-q. Ann Neurol. 1999. PMID: 10589537 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

136 results

Results by year